Welcome to our dedicated page for Monte Rosa Therapeutics news (Ticker: GLUE), a resource for investors and traders seeking the latest updates and insights on Monte Rosa Therapeutics stock.
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines. The GLUE news page on Stock Titan highlights company announcements that reflect progress across its oncology, immunology, and inflammation programs, as well as its capital markets and collaboration activities.
Investors following Monte Rosa news will see updates on its key clinical candidates, including MRT-2359, a GSPT1-directed MGD being evaluated in MYC-driven solid tumors such as metastatic castration-resistant prostate cancer, and MRT-8102, a NEK7-directed MGD in Phase 1 development for inflammatory diseases driven by the NLRP3 inflammasome, IL-1β, and IL-6. News items also cover MRT-6160, a VAV1-directed MGD for immune-mediated diseases being advanced with Novartis, and preclinical programs targeting cyclin E1 and CDK2.
Typical GLUE news coverage includes clinical trial updates (interim Phase 1 and Phase 1/2 data, study expansions, and planned Phase 2 trials), scientific presentations at major conferences, and collaboration milestones with partners such as Novartis and Roche. Financial and corporate releases, including quarterly results, cash runway commentary, and details of public offerings of common stock and pre-funded warrants, provide additional context on the company’s funding strategy.
By reviewing Monte Rosa’s news feed, readers can track how the company’s QuEEN™ discovery engine is translated into clinical programs, follow the evolution of its MGD pipeline in oncology and immune-mediated diseases, and monitor material events disclosed through press releases that are often cross-referenced in SEC filings. Bookmark this page to access a consolidated view of GLUE-related announcements as they are released.
Monte Rosa Therapeutics (Nasdaq: GLUE) priced an underwritten public offering of 11,125,000 common shares at $24.00 per share and pre-funded warrants to purchase 1,375,000 shares at $23.9999 each. Gross proceeds are expected to be approximately $300 million, before underwriting discounts, commissions and expenses. The company granted underwriters a 30-day option to buy up to an additional 1,875,000 shares. All offered securities are being sold by Monte Rosa and the offering is expected to close on or about January 12, 2026, subject to customary closing conditions.
Jefferies, TD Cowen and Piper Sandler are joint book-running managers; Wedbush PacGrow and LifeSci Capital are passive bookrunners. The offering is made under an effective shelf registration statement declared effective March 31, 2025.
Monte Rosa Therapeutics (Nasdaq: GLUE) announced a proposed underwritten public offering of $200.0 million of common stock and, for certain investors, pre-funded warrants to purchase common stock, with underwriters granted a 30-day option to buy up to an additional $30.0 million. The offering is subject to market and other conditions and may not be completed as proposed. The securities will be offered under an effective shelf registration declared effective by the SEC on March 31, 2025. Jefferies, TD Cowen and Piper Sandler are joint book-running managers; Wedbush PacGrow and LifeSci Capital are passive bookrunners. A preliminary prospectus supplement will be filed with the SEC.
Monte Rosa Therapeutics (NASDAQ: GLUE) announced positive interim Phase 1 data for MRT-8102, a NEK7-directed oral molecular glue degrader targeting NLRP3/IL-1/IL-6 inflammation pathways. In Part 3 (24 subjects dosed for 4 weeks as of Dec 23, 2025) median hsCRP fell 85% and 94% of subjects reached hsCRP <2 mg/L from a median baseline of 6.3 mg/L. NEK7 degradation in peripheral T cells was ~80–90% across doses (5–400 mg). Median plasma IL-6 dropped 55%; two subjects had a 75% CSF IL-6 decrease. Safety was described as favorable with mainly mild–moderate AEs and no evidence of increased infection risk. Readout of the expanded study is anticipated in H2 2026, and a Phase 2 ASCVD study is planned for 2026.
Monte Rosa Therapeutics (Nasdaq: GLUE) will present interim clinical results for the NEK7-directed molecular glue degrader MRT-8102 on Jan 7, 2026 at 8:00 a.m. ET. The presentation will highlight interim data from the ongoing Phase 1 study, including the Part 3 CRP proof-of-concept cohort in subjects with elevated cardiovascular disease risk.
The event will be available via live conference call and webcast through the company’s Events & Presentations page at ir.monterosatx.com, with an archived webcast accessible for 30 days after the presentation.
Monte Rosa Therapeutics (Nasdaq: GLUE)MRT-2359 plus enzalutamide in heavily pretreated mCRPC patients as of Dec 3, 2025. Of 20 enrolled (14 RECIST-evaluable), the AR-mutant subgroup (4 patients) showed a 100% PSA response rate (4/4), including two PSA90s, and a 100% disease control rate with two RECIST responses. Overall RECIST-evaluable DCR was 64% (9/14). Safety was manageable, primarily Grade 1–2 gastrointestinal events. The company plans a signal-confirming Phase 2 (up to 25 patients) beginning in 2026 and will present updated data at ASCO GU in Feb 2026.
Monte Rosa Therapeutics (Nasdaq: GLUE) will present updated interim results from the Phase 1/2 study of the GSPT1-directed molecular glue degrader MRT-2359 in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.
The company will host a live conference call and webcast on December 16, 2025 at 8:00 a.m. ET. The presentation will be available via Monte Rosa’s investor site under “Events & Presentations,” and an archived webcast will be accessible for 30 days after the event.
Monte Rosa Therapeutics (Nasdaq: GLUE) will present preclinical data on MRT-8102, a first-in-class NEK7-directed molecular glue degrader, at AHA Scientific Sessions 2025 on Nov 8, 2025 at 10:30 a.m. CST.
Key findings showed selective, potent, and durable NEK7 degradation with in vitro and in vivo inhibition of the NLRP3 inflammasome, suppression of multiple cytokines, inhibition of pyroptosis in human macrophages, and near-complete IL-1β and Caspase-1 suppression in ex vivo whole blood from orally dosed cynomolgus monkeys. The company is enrolling a Phase 1 study and expects initial healthy-volunteer and elevated CVD-risk data in H1 2026.
Monte Rosa Therapeutics (Nasdaq: GLUE) reported Q3 2025 results and business updates highlighting a new collaboration with Novartis and multiple clinical programs advancing.
Key facts: $120.0M non-refundable upfront from Novartis, up to $5.7B total deal value, Q3 collaboration revenue $12.8M, cash and marketable securities $396.2M as of Sept 30, 2025, and a stated cash runway to fund operations through 2028. Clinical highlights include MRT-8102 Phase 1 initial readout on track for H1 2026, MRT-6160 advancing toward Phase 2 with Novartis, and MRT-2359 updated data expected by year-end 2025. Company plans IND submissions in 2026.
Monte Rosa Therapeutics (Nasdaq: GLUE) announced that CEO Markus Warmuth, M.D. will participate in fireside chats at four investor conferences in November–December 2025.
Scheduled participations: Guggenheim Healthcare Innovation (Boston) on Nov 10, 2025 at 11:30 a.m. ET; TD Cowen Immunology & Inflammation Summit (virtual) on Nov 13, 2025 at 12:00 p.m. ET; Jefferies Global Healthcare (London) on Nov 18, 2025 at 11:30 a.m. GMT; and Piper Sandler Healthcare (New York) on Dec 2, 2025 at 1:30 p.m. ET.
Webcasts will be available via the company’s Events & Presentations page at ir.monterosatx.com and archived for 30 days after each presentation.
Monte Rosa Therapeutics (Nasdaq: GLUE) announced preclinical data for MRT-6160, a VAV1-directed molecular glue degrader, showing broad activity in immune cells and disease reduction in a spontaneous autoimmune MRL-Faslpr mouse model.
Key reported effects include attenuated autoantibody production, reduced proteinuria, lymphadenopathy, skin lesions, organomegaly, and kidney glomerular and interstitial nephritis. The company reported MRT-6160 was equivalent or superior to prednisone and an anti-CD40L antibody across multiple pathology metrics. In vitro, MRT-6160 decreased TfH-mediated B cell activation and immunoglobulin secretion. Monte Rosa said it continues to work with Novartis to advance MRT-6160 toward Phase 2 studies. Poster presentation: October 26, 2025, 10:30–12:30 pm CDT (Poster #0009).
FAQ
What is the current stock price of Monte Rosa Therapeutics (GLUE)?
What is the market cap of Monte Rosa Therapeutics (GLUE)?
